RUI ZHOU^#, JIANYANG XU^#, LINGWEI WANG^*, JIANXIN LI^*

Oncology Research, Vol.29, No.6, pp. 411-423, 2021, DOI:10.32604/or.2022.026236 - 10 November 2022

Abstract Long noncoding RNAs (lncRNAs) act as key regulators controlling complex cellular behaviors in nonsmall cell lung cancer (NSCLC). We investigated the expression of lncRNA PRRT3 antisense RNA 1 (PRRT3-AS1) in paired samples of NSCLC and adjacent normal tissues from a patient cohort in our hospital using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and found that it was significantly higher in NSCLC tissue than in normal tissue, consistent with The Cancer Genome Atlas database. Furthermore, functional investigation revealed that lncRNA PRRT3-AS1 depletion inhibited NSCLC-cell proliferation, colony formation, invasion, and migration, whereas its overexpression exerted… More >

MARGARET SIMONIAN^*

BIOCELL, Vol.45, No.6, pp. 1459-1463, 2021, DOI:10.32604/biocell.2021.017369 - 01 September 2021

Abstract Pediatric central nervous system tumors are the most common tumors in children, it constitute 15%–20% of all malignancies in children and are the leading cause of cancer related deaths in children. Proteogenomics is an emerging field of biological research that utilizes a combination of proteomics, genomics, and transcriptomics to aid in the discovery and identification of biomarkers for diagnosis and therapeutic purposes. Integrative proteogenomics analysis of pediatric tumors identified underlying biological processes and potential treatments as well as the functional effects of somatic mutations and copy number variation driving tumorigenesis. More >

Keiichi Kontani^1,*, Kana Kuraishi¹, Shin-ichiro Hashimoto¹, Shoko Norimura², Nozomi Hashimoto¹, Masahiro Ohtani³, Naomi Fujiwara-Honjo⁴, Manabu Date⁵, Koji Teramoto⁶, Hiroyasu Yokomise¹

Oncologie, Vol.23, No.2, pp. 229-239, 2021, DOI:10.32604/Oncologie.2021.016277 - 22 June 2021

Abstract The prognosis of patients with human epidermal growth factor receptor-2 (HER2)-overexpressed metastatic breast cancer (MBC) has improved drastically following the development of anti-HER2 therapies. We question what factors are involved in the improved outcome by the treatment. One hundred and two MBC patients who received chemotherapy were classified into groups according to breast cancer subtype: luminal/HER2-negative (n = 50), HER2 (n = 26), and triple-negative subtypes (n = 26). Clinicopathologic features and clinical outcomes of the groups were compared. Disease-free intervals in the triple-negative group were significantly shorter than those in the other two groups.… More >

Linn Woelber^*1, Sabrina Mathey^*1, Katharina Prieske^*†, Sascha Kuerti^*, Christoph Hillen^*, Eike Burandt^‡, Anja Coym^§, Volkmar Mueller^*, Barbara Schmalfeldt^*, Anna Jaeger^*

Oncology Research, Vol.28, No.6, pp. 645-659, 2020, DOI:10.3727/096504020X16076861118243

Abstract Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one… More >

Guojie Chen^*1, Kai Wang^*1, Guoshu Li^†1, Leidong Wang^‡, Yangyang Xiao^§, Bo Chen^¶

Oncology Research, Vol.28, No.9, pp. 945-959, 2020, DOI:10.3727/096504021X16328213967104

Abstract Long noncoding RNA LAMTOR5 antisense RNA 1 (LAMTOR5-AS1) has been certified as a risk predictor and diagnostic biomarker of prostate cancer. However, the expression and exact roles of LAMTOR5-AS1 in nonsmall cell lung cancer (NSCLC) remain unclear. Thus, we measured LAMTOR5-AS1 expression in NSCLC and gauged its clinical value. The detailed roles and downstream working mechanism of LAMTOR5-AS1 in NSCLC were comprehensively unraveled. qRT-PCR was applied to measure gene expression. Functionally, utilizing small interfering RNA, LAMTOR5-AS1 was ablated, and the functional alterations were addressed by means of different experiments. The targeting activities between LAMTOR5-AS1 and… More >

Huan Ma¹, Cong Nie¹, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai, Yuxiang Mao, Qian Sun, Rong Lu

Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507

Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by ON-01910.Na was tumor specific and… More >

Nishant Patel¹, Jason Woo¹, Michael A. Liss¹, Kerrin L. Palazzi¹, J. Michael Randall², Reza Mehrazin³, Ramzi Jabaji¹, Hossein S. Mirheydar¹, Kyle Gillis¹, Hak J. Lee¹, Anthony L. Patterson³, Christopher J. Kane¹, Frederick Millard², Ithaar H. Derweesh¹

Canadian Journal of Urology, Vol.23, No.2, pp. 8227-8233, 2016

Abstract Introduction: To compare surgical complications and tyrosine kinase inhibitor (TKI)-toxicities in patients who underwent primary cytoreductive nephrectomy (CN) followed by adjuvant TKI therapy versus those who underwent neoadjuvant TKI therapy prior to planned CN for metastatic renal cell carcinoma (mRCC).
Materials and methods: Two-center retrospective analysis. Sixty-one mRCC patients underwent TKI therapy with sunitinib between July 2007 to January 2014. Patients were divided into three groups: primary CN followed by adjuvant TKI (n = 27, Group 1), neoadjuvant TKI prior to CN (n = 21, Group 2), and primary TKI alone (no surgery, n = 13, Group… More >

Uzma Athar, Teresa C. Gentile

Canadian Journal of Urology, Vol.15, No.2, pp. 3954-3966, 2008

Abstract Metastatic renal cell carcinoma (RCC) has a poor overall survival. Localized RCC remains a surgical disease. About 20%-30% patients who present with limited disease at the time of nephrectomy develop metastasis. The median time to relapse after nephrectomy is 15-18 months. The maximum numbers of relapses are within the first 3 years. In metastatic RCC, immunotherapy is effective in a relatively small percentage of patients but is very toxic. In recent years, there has been an improved understanding of the biology of RCC. This has lead to the development of various agents that target ligands More >